Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.51 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.41 |
| ▸ | SGK1 | O00141 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TRIM58 | Q8NG06 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 3/20 | 0.38 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2494065 | 0.81 | LOXL2 (0.58) | LOXL2AAK1 | |
| SCHEMBL25820095 | 0.78 | HTR1A (0.51) | LOXL2CYP19A1 | |
| SCHEMBL25820075 | 0.77 | CCNC (0.42) | AAK1 | |
| SCHEMBL25820130 | 0.77 | KDM4E (0.43) | LOXL2 | |
| SCHEMBL25820113 | 0.76 | AAK1 (0.32) | MAP4K4CLK1DYRK1AAAK1 | |
| SCHEMBL25820138 | 0.75 | TRPV1 (0.45) | — | |
| SCHEMBL25820094 | 0.75 | SLC22A12 (0.42) | LOXL2CYP19A1DYRK1A | |
| SCHEMBL25820108 | 0.75 | IP6K1 (0.43) | LOXL2 | |
| SCHEMBL8677931 | 0.74 | PIK3CA (0.59) | PIK3CAMAPKAPK2MAP4K4ALKTRIM58 | |
| SCHEMBL24026944 | 0.74 | TRIM58 (0.40) | PIK3CAMAP4K4CAMKK2SGK1TRIM58 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | PIK3CA 7/4885MAPKAPK2 138/4885MAP4K4 323/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | PIK3CA 3/4885MAPKAPK2 136/4885MAP4K4 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.